晚期非小细胞肺癌靶向治疗的研究进展

姜文丽; 黄才国

doi:10.3969/j.issn.1006-0111.2016.04.004

晚期非小细胞肺癌靶向治疗的研究进展

doi: 10.3969/j.issn.1006-0111.2016.04.004

第二军医大学基础部生物化学与分子生物学教研室, 上海 200433

基金项目: 国家自然科学基金面上项目（41576160，81473239）

Research progress on target therapy of advanced non-small cell lung cancer

Department of Biochemistry and Molecular Biology, Faculty of Basic Medicine, Second Military Medical University, Shanghai 200433, China

摘要: 生物标志物检测使得许多晚期非小细胞肺癌（NSCLC）患者获益。近年来，针对表皮生长因子受体（EGFR）和间变性淋巴瘤激酶（ALK）突变呈阳性的NSCLC患者，以吉非替尼、厄洛替尼、阿法替尼为代表的表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）和以克唑替尼为代表的ALK-TKI取得了卓越的疗效。但是，大多数第一代EGFR-TKI和ALK-TKI的疗效因为不可避免的继发性耐药而被减弱。目前，第三代EGFR-TKI正是基于第二代EGFR-TKI的耐药机制研发而成。除此之外，还有许多针对其他突变位点的晚期NSCLC维持治疗的靶向抑制剂。遗憾的是，针对突变比例最大的K-RAS突变，尚无疗效确切的靶向药物。因此，基于肿瘤驱动基因突变机制的探索和靶向药物的开发是目前NSCLC的研究热点。
- 非小细胞肺癌 /
- 靶向药物 /
- 肿瘤
Abstract: Detection of biomarkers benefited many advanced non-small cell lung cancer (NSCLC) patients. In recent years, epidermal growth factor (EGFR) tyrosine kinase inhibitors (TKIs) represented by Gefitinib, Erlotinib, Afatinib and anaplastic lymphoma kinase (ALK) TKIs represented by Crizotinib have remarkable efficacy. However, the efficacy for most first-generation EGFR-TKI and ALK-TKI is weakened due to secondary resistance. Currently, the third-generation EGFR-TKI which successfully against drug resistance is based on research and development of the second-generation. In addition, there are many other targeted inhibitors of mutation sites for advanced NSCLC. Unfortunately, the largest proportion of Kirsten rat sarcoma viral oncogene homolog (K-RAS) mutation is not targetable with small molecule inhibitors currently. Therefore, based on mechanisms exploration of tumor driven gene mutation, its target drug research and development will be greatly addressed in the future.
- non-small cell lung cancer (NSCLC) /
- molecular targeting agents /
- tumour

[1]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132.
[2]	Jorge S, Kobayashi SS, Costa DB. Epidermal growth factor receptor (EGFR) mutations in lung cancer:preclinical and clinical data[J]. Brazil J Med Biolog Res, 2014,47(11):929-939.
[3]	Sequist LV, Yang JC, Yamamoto N, et al. Phase Ⅲ study of Afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations[J]. J Clin Oncol, 2013, 31(27):3327-3334.
[4]	Banno E, Togashi Y, Kobayashi Y, et al. Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion[J]. Anticancer Res, 2015,35(4):2005-2008.
[5]	Karachaliou N, Mayo-de las Casas C, Queralt C, et al. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial[J]. JAMA Oncol, 2015,1(2):149-157.
[6]	Sadek M, Alexakis A, Fauve S. OPTIMAL length scale for a turbulent dynamo[J]. Phys Rev Lett, 2016, 116(7):074501.
[7]	Choi SH, Mendrola JM, Lemmon MA. EGF-independent activation of cell-surface EGF receptors harboring mutations found in Gefitinib-sensitive lung cancer[J]. Oncogene, 2007, 26(11):1567-1576.
[8]	Steuer CE, Ramalingam SS. Targeting EGFR in lung cancer:Lessons learned and future perspectives[J]. Mol Aspects Med, 2015, 45:67-73.
[9]	Vacondio F, Carmi C, Galvani E, et al. Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors[J]. Bioorg Med Chem Lett, 2013, 23(19):5290-5294.
[10]	Giordano P, Manzo A, Montanino A, et al. Afatinib:An overview of its clinical development in non-small-cell lung cancer and other tumors[J]. Crit Rev Oncol Hematol, 2016, 97:143-151.
[11]	Kato T, Yoshioka H, Okamoto I, et al. Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations:Subgroup analysis of LUX-Lung 3[J]. Cancer Sci, 2015, 106(9):1202-1211.
[12]	Soria JC, Felip E, Cobo M, et al. Afatinib versus Erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8):an open-label randomised controlled phase 3 trial[J]. Lancet Oncol, 2015, 16(8):897-907.
[13]	Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer[J]. N Engl J Med, 2015, 372(18):1689-1699.
[14]	Greig SL. Osimertinib:First global approval[J]. Drugs, 2016, 76(2):263-273.
[15]	Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements:Latest evidence and treatment approaches[J]. Ther Adv Respir Dis, 2016, 10(2):113-129.
[16]	Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers[J]. Clin Cancer Res, 2013, 19(8):2240-2247.
[17]	Chong CR, Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer[J]. Nat Med, 2013,19(11):1389-1400.
[18]	Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models[J]. Oncogene, 2008, 27(34):4702-4711.
[19]	Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J]. Nature, 2007, 448(7153):561-566.
[20]	Cameron L, Solomon B. New treatment options for ALK-rearranged non-small cell lung cancer[J]. Curr Treat Options Oncol, 2015, 16(10):49.
[21]	Costa DB, Shaw AT, Ou SH, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases[J]. J Clin Oncol, 2015,33(17):1881-1888.
[22]	Lukas RV, Hasan Y, Nicholas MK, et al. ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy[J]. J Clin Neurosci, 2015,22(12):1978-1979.
[23]	Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations[J]. J Clin Oncol,2011,29(26):3574-3579.
[24]	石远凯,孙燕,于金明,等.中国晚期原发性肺癌诊治专家共识(2016年版)[J].中国肺癌杂志,2016,19(1):1-15.
[25]	Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies[J]. Nat Med, 2012, 18(3):382-384.
[26]	Li BT, Ross DS, Aisner DL, et al. HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers[J]. J Thorac Oncol, 2016, 11(3):414-419.
[27]	Mar N, Vredenburgh JJ, Wasser JS. Targeting HER2 in the treatment of non-small cell lung cancer[J]. Lung Cancer, 2015, 87(3):220-225.

[1]	陈怡君, 王卓, 何苗, 张宇, 田泾. 泌尿系统碎石术抗菌药物预防使用合理管控实践 . 药学实践与服务, 2025, 43(12): 1-5. doi: 10.12206/j.issn.2097-2024.202402034
[2]	张岩, 李炎君, 刘家荟, 邓娇, 原苑, 张敬一. 药物性肝损伤不良反应分析 . 药学实践与服务, 2025, 43(1): 26-29, 40. doi: 10.12206/j.issn.2097-2024.202404034
[3]	魏莱, 董国强, 盛春泉. 靶向SARS-CoV-2主蛋白酶的PROTAC设计、合成与蛋白降解活性研究 . 药学实践与服务, 2025, 43(5): 235-241, 258. doi: 10.12206/j.issn.2097-2024.202503063
[4]	柯刚, 董清科, 肖世容, 龚茜, 李荣, 汪代杰. 基于网络药理学探讨参苓白术散治疗肿瘤恶病质的作用机制 . 药学实践与服务, 2025, 43(5): 242-250. doi: 10.12206/j.issn.2097-2024.202208115
[5]	施乔, 韩贵焱, 张俊腾, 刘娜. 新型Hsp90抑制剂的设计合成及其抗真菌和抗肿瘤活性研究 . 药学实践与服务, 2025, 43(3): 124-135. doi: 10.12206/j.issn.2097-2024.202501019
[6]	吴若南, 汤文敏, 高林, 吴岳林, 罗川, 缪震元. RRx-001衍生物的合成和抗肿瘤活性研究 . 药学实践与服务, 2025, 43(8): 400-403. doi: 10.12206/j.issn.2097-2024.202408053
[7]	宋天豪, 许维恒, 王彦, 陈莉. 肝癌肿瘤微环境的研究进展 . 药学实践与服务, 2025, 43(): 1-6. doi: 10.12206/j.issn.2097-2024.202504126
[8]	周娇, 郑建雨, 王思真, 杨峰. mRNA肿瘤疫苗非病毒递送系统研究进展 . 药学实践与服务, 2025, 43(3): 109-116. doi: 10.12206/j.issn.2097-2024.202410034
[9]	李娜, 黄诚文, 孙秀娟, 王晓红, 张丽, 王兴坡. 奥希替尼与吉非替尼治疗表皮生长因子受体突变的晚期非小细胞肺癌的成本效果分析 . 药学实践与服务, 2025, 43(12): 608-613. doi: 10.12206/j.issn.2097-2024.202411032
[10]	陈明, 王晨佳, 唐原君, 汪硕闻, 范国荣. 新型靶向抗肿瘤药物呋喹替尼的治疗药物监测方法构建及其临床应用 . 药学实践与服务, 2025, 43(12): 1-4. doi: 10.12206/j.issn.2097-2024.202412043
[11]	陈官旭, 宋雨桐, 郭秀强, 张咪, 刘志宏, 宋洪涛. EGFR-TKIs单药及其联合方案在晚期非小细胞肺癌一线治疗中的疗效与安全性比较：网状Meta分析 . 药学实践与服务, 2025, 43(): 1-11. doi: 10.12206/j.issn.2097-2024.202504044
[12]	胡越, 殷勇, 徐晓红, 施柳辉, 朱建勇, 年华. 基于网络药理学探讨夏枯草消瘤合剂治疗非小细胞肺癌的作用机制 . 药学实践与服务, 2025, 43(12): 1-8. doi: 10.12206/j.issn.2097-2024.202302020
[13]	何亚伦, 祁智, 常杰. 消胀通便膏在晚期肝癌患者阿片类药物相关性便秘中的应用研究 . 药学实践与服务, 2024, 42(12): 520-523. doi: 10.12206/j.issn.2097-2024.202309009
[14]	夏哲炜, 曾垣烨, 朱海菲, 李育, 陈啸飞. 核磁共振磷谱法测定磷酸氢钙咀嚼片中药物含量 . 药学实践与服务, 2024, 42(9): 399-401, 406. doi: 10.12206/j.issn.2097-2024.202404063
[15]	孙丹倪, 黄勇, 张嘉宝, 王培. 代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
[16]	张元林, 宋凯, 孙蕊, 舒飞, 舒丽芯, 杨樟卫. 基于真实世界数据的药物利用研究综述 . 药学实践与服务, 2024, 42(6): 238-243. doi: 10.12206/j.issn.2097-2024.202312010
[17]	马兹芬, 许维恒, 金煜翔, 薛磊. 食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
[18]	唐淑慧, 凤美娟, 薛智霞, 鲁桂华. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
[19]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
[20]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023

点击查看大图

计量

文章访问数: 4909
HTML全文浏览量: 322
PDF下载量: 1730
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

晚期非小细胞肺癌靶向治疗的研究进展

doi: 10.3969/j.issn.1006-0111.2016.04.004

Research progress on target therapy of advanced non-small cell lung cancer

计量

晚期非小细胞肺癌靶向治疗的研究进展

doi: 10.3969/j.issn.1006-0111.2016.04.004

第二军医大学基础部生物化学与分子生物学教研室, 上海 200433

English Abstract

Research progress on target therapy of advanced non-small cell lung cancer

Department of Biochemistry and Molecular Biology, Faculty of Basic Medicine, Second Military Medical University, Shanghai 200433, China

全文HTML

目录

留言板

晚期非小细胞肺癌靶向治疗的研究进展

doi: 10.3969/j.issn.1006-0111.2016.04.004

Research progress on target therapy of advanced non-small cell lung cancer

计量

出版历程

晚期非小细胞肺癌靶向治疗的研究进展

doi: 10.3969/j.issn.1006-0111.2016.04.004

第二军医大学基础部生物化学与分子生物学教研室, 上海 200433

English Abstract

Research progress on target therapy of advanced non-small cell lung cancer

Department of Biochemistry and Molecular Biology, Faculty of Basic Medicine, Second Military Medical University, Shanghai 200433, China

全文HTML

目录